Study for the effects of vildagriptin in combination with metformin on vascular endothelial function and systemic metabolism in patients with type 2 diabetes -multicenter, prospective, randomized, open-label, parallel group comparison- - Study for the effects of vildagriptin in combination with metformin on vascular endothelial function and systemic metabolism in type 2 DM patients

Study group for the treatment of type 2 diabetes in Sapporo0 个研究点目标入组 110 人开始时间: 2013年6月28日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) patients who receive insulin injection therapy, 2) severe respiratory disease, renal dysfunction and heart disease, 3) moderate or severe renal dysfunction (1.3 and 1.2 mg/dL or more for male and female, respectively), 4) hepatitis or hepatocirrhosis (AST/GOT or ALT/GPT: 100U or more), 5) malignant tumor, 6) history of angina, myocardial infarction, stroke or arteriosclerotic diseases, 7) patients who receive thiazolidinediones, alpha-glucosidase inhibitor, GLP-1 receptor agonist or DPP-4 inhibitor in 8 weeks, 8) hypersensitivity to study drugs on this study, 9) pregnancy, nursing woman or possibly pregnant woman, 10) patients who are inadequate to enter this study due to the other reasons by physician's judgments

发起方

Study group for the treatment of type 2 diabetes in Sapporo